9 results on '"R. Ridolfi"'
Search Results
2. Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer.
- Author
-
Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Fonsatti E, Papamichail M, and Parmiani G
- Subjects
- Animals, Humans, Neoplasms immunology, Immunotherapy methods, Neoplasms therapy
- Published
- 2012
- Full Text
- View/download PDF
3. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
- Author
-
Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, and Maio M
- Subjects
- Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal immunology, CTLA-4 Antigen immunology, Disease Progression, Female, Humans, Ipilimumab, Male, Melanoma immunology, Melanoma pathology, Middle Aged, Neoplasm Metastasis, Uveal Neoplasms immunology, Uveal Neoplasms pathology, Antibodies, Monoclonal therapeutic use, Melanoma drug therapy, Uveal Neoplasms drug therapy
- Abstract
Current systemic treatments for metastatic uveal melanoma (UM) have not improved overall survival (OS). The fully human anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, ipilimumab, improved OS of patients with advanced cutaneous melanoma in a phase 3 trial; however, UM patients were excluded. The aim of this subanalysis, performed by the ipilimumab-ocular melanoma expanded access program (I-OMEAP) study group, was to assess the activity and safety of ipilimumab in patients with UM in a setting similar to daily clinical practice. Patients participating in a multicenter expanded access program (EAP) received induction treatment with ipilimumab 10 mg/kg. Maintenance doses were administered in patients who experienced clinical benefit or at physicians' discretion. Tumor assessment was evaluated per modified World Health Organization criteria at baseline, Week 12, Week 24, and Week 36. Adverse events (AEs) and immune-related AEs (irAEs) were collected according to Common Terminology Criteria for Adverse Events version 3.0. Thirteen pretreated patients with metastatic UM were treated at 6 European institutions. All patients received at least one dose of ipilimumab. Overall, no objective responses were observed; however, two patients had stable disease (SD), with a third patient achieving SD after initial progressive disease. Median OS as of July 1, 2011, was 36 weeks (range 2-172+ weeks). No grade 3/4 AEs of non-immune origin were reported. Three patients (23%) experienced grade 3 irAEs (1 thrombocytopenia, 1 diarrhea, and 1 alanine/aspartate aminotransferase elevation) that resolved with steroid therapy. The results indicate UM is a potential indication for ipilimumab treatment that should be further investigated in clinical trials.
- Published
- 2012
- Full Text
- View/download PDF
4. Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.
- Author
-
Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, and Parmiani G
- Subjects
- Humans, Immunotherapy methods, Neoplasms immunology, Neoplasms therapy
- Published
- 2011
- Full Text
- View/download PDF
5. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.
- Author
-
Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, and Parmiani G
- Subjects
- Angiogenesis Inhibitors therapeutic use, Cancer Vaccines immunology, Dendritic Cells immunology, Humans, Immune Tolerance, Immunotherapy, Adoptive, Neoplasms immunology, Tumor Escape, Vaccination, Neoplasms therapy
- Published
- 2010
- Full Text
- View/download PDF
6. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.
- Author
-
Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, and Parmiani G
- Subjects
- Animals, Diagnostic Imaging, Humans, Immunologic Surveillance, Information Services, Italy, Neoplasms therapy, Neoplastic Stem Cells immunology, Organizations, Nonprofit, Cancer Vaccines, International Cooperation, Neoplasms immunology
- Published
- 2010
- Full Text
- View/download PDF
7. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
- Author
-
Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, and Amadori D
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms pathology, Capecitabine, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine therapeutic use, Dose-Response Relationship, Drug, Doxorubicin adverse effects, Doxorubicin therapeutic use, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Maximum Tolerated Dose, Medication Adherence, Middle Aged, Neoplasm Metastasis, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms drug therapy, Deoxycytidine analogs & derivatives, Doxorubicin administration & dosage, Fluorouracil analogs & derivatives
- Abstract
Purpose: Anthracyclines and fluoropyrimidines are very active in breast cancer, while liposomal doxorubicin has low cardiotoxicity. We conducted a dose-finding study of the combination of liposomal doxorubicin and capecitabine in patients with pretreated metastatic breast cancer., Patients and Methods: Patients received liposomal doxorubicin 60 mg/m2 on day 1 plus capecitabine 825 mg/m2 bid (level 0) or 1,000 mg/m2 bid (level 1) on days 1-14 of each 21-day cycle to establish the maximum tolerated dose (MTD) and cardiac safety., Results: Nine patients were enrolled and a total of 52 courses were delivered (median 6 cycles per patient [range 4-7]). Grade 4 neutropenia occurred in 15% of cycles, with one episode of febrile neutropenia; most nonhematological toxicities were mild or moderate. No formal MTD was established, and the study was closed because two cardiac events were observed at dose level 1 and another at dose level 0 in patients pretreated with epirubicin > or = 560 mg/m2., Conclusions: The recommended dose for phase II studies is liposomal doxorubicin 60 mg/m2 on day 1 plus capecitabine 825 mg/m2/bid on days 1-14 of each 21-day cycle. Despite the lower cardiotoxicity of liposomal doxorubicin, the risk of cardiac damage persists in anthracycline-pretreated individuals and mandates close cardiac monitoring and careful evaluation of the overall cumulative dose.
- Published
- 2010
- Full Text
- View/download PDF
8. Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome.
- Author
-
Venanzi FM, Petrini M, Fiammenghi L, Bolli E, Granato AM, Ridolfi L, Gabrielli F, Barucca A, Concetti A, Ridolfi R, and Riccobon A
- Subjects
- Adult, Aged, Cancer Vaccines immunology, Cancer Vaccines metabolism, Carcinoma, Renal Cell immunology, Carcinoma, Renal Cell therapy, Dendritic Cells immunology, Female, Humans, Male, Melanoma immunology, Microfilament Proteins, Middle Aged, Neoplasm Proteins immunology, Receptors, Cell Surface immunology, Vaccination, Cancer Vaccines therapeutic use, Dendritic Cells metabolism, Melanoma therapy, Neoplasm Proteins biosynthesis, Receptors, Cell Surface biosynthesis
- Abstract
Previous studies have shown that tumor endothelial markers (TEMs 1-9) are up modulated in immunosuppressive, pro-angiogenic dendritic cells (DCs) found in tumor microenvironments. We recently reported that monocyte-derived DCs used for vaccination trials may accumulate high levels of TEM8 gene transcripts. Here, we investigate whether TEM8 expression in DC preparations represents a specific tumor-associated change of potential clinical relevance. TEM8 expression at the mRNA and protein level was evaluated by quantitative real-time RT-PCR and cytofluorimetric analysis in human clinical grade DCs utilized for the therapeutic vaccination of 17 advanced cancer patients (13 melanoma and 4 renal cell carcinoma). The analyses revealed that DCs from patients markedly differ in their ability to up-modulate TEM8. Indeed, mDCs from eight non-progressing patients [median overall survival (OS) = 32 months, all positive to the delayed-type hypersensitivity test (DTH)], had similar TEM8 mRNA expression levels [mDCs vs. immature iDCs; mean fold increase (mfi) = 1.97] to those found in healthy donors (mfi = 2.7). Conversely, mDCs from nine progressing patients (OS < 5 months, all but one with negative DTH) showed an increase in TEM8 mRNA levels (mfi = 12.88, p = 0.0018). The present observations suggest that TEM8 expression levels in DC-based therapeutic vaccines would allow the selection of a subgroup of patients who are most likely to benefit from therapeutic vaccination.
- Published
- 2010
- Full Text
- View/download PDF
9. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
- Author
-
Ridolfi R, Flamini E, Riccobon A, De Paola F, Maltoni R, Gardini A, Ridolfi L, Medri L, Poletti G, and Amadori D
- Subjects
- Adolescent, Adult, Aged, Colorectal Neoplasms pathology, Combined Modality Therapy, Female, Humans, Interleukin-2 adverse effects, Kidney Neoplasms pathology, Liver Neoplasms secondary, Liver Neoplasms surgery, Lung Neoplasms secondary, Lung Neoplasms surgery, Lymphatic Metastasis, Male, Melanoma secondary, Melanoma surgery, Middle Aged, Skin Neoplasms secondary, Skin Neoplasms surgery, Colorectal Neoplasms therapy, Immunotherapy, Adoptive, Interleukin-2 therapeutic use, Kidney Neoplasms therapy, Lymphocytes, Tumor-Infiltrating immunology, Melanoma therapy
- Abstract
Adoptive tumour infiltrating lymphocytes (TIL) in combination with a modulated dosage of interleukin-2 (IL-2) can be used with acceptable toxicity in the treatment of immunogenic tumours. Following an experience of reinfusion in advanced melanoma, colorectal and renal cancer patients, treatment was given to disease-free patients after metastasectomy. The high risk of relapse and favourable ratio between reinfused TIL and possible microscopic residual disease determined this choice of adjuvant treatment. A group of 12 patients with advanced disease (7 melanoma, 4 colorectal carcinoma, 1 kidney carcinoma) were treated with TIL (median 5.8 x 10(10) cells) and IL-2 (West's schedule) modulated towards a lower dosage (from 12 to 6 MIU/day) in order to maintain an acceptable level of toxicity. As treatment was well tolerated, it was offered to another 22 patients in an adjuvant setting after metastasectomy (11 melanoma, 10 colorectal carcinoma, 1 renal cancer), the median dose of TIL reinfused being 4.95 x 10(10) cells. No objective response was observed in advanced patients: all patients progressed after a median of 1.5 months (0-8 months) and median survival was 8 months (3-22+ months). Thirteen patients from the second group are still disease-free after a median of 23+ months (9+ - 47+ months). The remaining 9 patients relapsed after a median of 5 months (3-18 months). Toxicity was moderate as clinical and hepatic/renal function parameters were used to assess the need for dose reductions. Consequently, there was great diversity in IL-2 dosages administered. In particular, there seemed to be a difference in IL-2 doses administered between disease-free cases and those who progressed (17.5 MIU/day versus 7 MIU/day in melanoma patients; 11.2 MIU/day versus 7.1 MIU/day in colorectal cancer patients). By contrast, no differences were observed between number of TIL reinfused and clinical response. Phenotypical characteristics of reinfused TIL were similar to those reported in the literature: 97% were CD3 and 92% were CD8. Aspecific cytolytic activity was evaluated on 12 cases whereas, in 2 melanoma cases, autologous tumour tissue was available for the specific cytotoxicity test. Perforin levels in TIL measured at the end of culture were generally high or very high. Cytokine levels were measured on the supernatant at the end of culture, with an estreme variability in results. Finally, delta chain and p56lck were histologically assessed on the resected tissue from which TIL were cultivated. There were virtually none of the former and a complete absence of the latter, which concurs with data reported in the literature. The same immunocytochemical analysis was carried out on TIL at the end of culture. This time an almost complete restoration of both functions was seen, especially in melanoma patients, who are still free from disease. The study is on-going and it has been decided to focus on disease-free patients after metastasectomy in order to increase the number and possibility of clinical and histological correlations.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.